ReviewInternational journal of molecular sciences2022
Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies.Journal of fungi (Basel, Switzerland) · 2025Review
- Antibodies and cryptographic hash functions: quantifying the specificity paradox.Frontiers in immunology · 2025Article
- Novel Monoclonal Antibodies 1D2 and 4E4 AgainstJournal of fungi (Basel, Switzerland) · 2024Article
- Effectiveness, Safety, and Patterns of Real-World Isavuconazole Use in Europe (2015-2019).Infectious diseases and therapy · 2024Article
- Rapid diagnosis ofFrontiers in medicine · 2024Article
- Humoral Immunity Against Aspergillus fumigatus.Mycopathologia · 2023Review
- Antifungal Drug Resistance: An Emergent Health Threat.Biomedicines · 2023Review
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Metagenomic Next-Generation Sequencing Assists in the Diagnosis of MediastinalInfection and drug resistance · 2023Article
- A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically ImportantJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Invasive aspergillosis (IA) is a life-threatening fungal disease that causes high morbidity and mortality in immunosuppressed patients. Early and accurate diagnosis and treatment of IA remain challenging. Given the broad range of non-specific clinical symptoms and the shortcomings of current diagnostic techniques, most patients are either diagnosed as "possible" or "probable" cases but not "proven". Moreover, because of the lack of sensitive and specific tests, many high-risk patients receive an empirical therapy or a prolonged treatment of high-priced antifungal agents, leading to unnecessary adverse effects and a high risk of drug resistance. More precise diagnostic techniques alongside a targeted antifungal treatment are fundamental requirements for reducing the morbidity and mortality of IA. Monoclonal antibodies (mAbs) with high specificity in targeting the corresponding antigen(s) may have the potential to improve diagnostic tests and form the basis for novel IA treatments. This review summarizes the up-to-date application of mAb-based approaches in assisting IA diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.